Total Credits:
.75
including
.75 AOA Category 1-A Credit(s)
- Average Rating:
-
Not yet rated
- Faculty:
-
William Elliott, M.D. Ph.D.
- Short Description:
- Physicians and medical professionals will learn why long-term randomized clinical trials against placebo were done to verify the cardiovascular safety of novel hypoglycemic agents. They will compare and contrast outcomes in randomized clinical trials for sodium-glucose-linked transporter-2 inhibitors, glucagon-like peptide-1 agonists, and dipeptidyl peptidase-4 inhibitors for cardiovascular or renal endpoints. They will be able to name the pharmacological agents (and their indications) that have received FDA approval for "benefits beyond glucose-lowering" with regard to preventing cardiovascular or renal endpoints.
- Price:
-
$30.00
- Base Price
